Antipruritics

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Monday, August 2, 2021
Life sciences, Drugs, Health sciences, Amines, Antipruritics, Difelikefalin, Piperidines, Biopharmaceutical, Investigational New Drug

ET to report second quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET to report second quarter 2021 financial results and provide a corporate update.
  • To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1568596.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547, an MrgprX4-Targeted Oral Therapy for Cholestatic and Uremic Pruritus

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Organ systems, Medical specialties, Hepatology, Uremic pruritus, Cholestasis, Itch, Antipruritics, Nalfurafine, EP547 for Cholestatic and Uremic Pruritus, Escient Pharmaceuticals, EP547 FOR CHOLESTATIC AND UREMIC PRURITUS, ESCIENT PHARMACEUTICALS

The study found that EP547 was safe and well-tolerated in both healthy volunteers and patients with chronic cholestatic or kidney disease at all doses tested.

Key Points: 
  • The study found that EP547 was safe and well-tolerated in both healthy volunteers and patients with chronic cholestatic or kidney disease at all doses tested.
  • EP547 was found to be safe and well-tolerated with no serious adverse events, no adverse events leading to discontinuation, and no safety signals identified.
  • By blocking these pruritogens from activating MrgprX4, Escient believes EP547 has the potential to effectively treat both cholestatic and uremic pruritus.
  • Drug development to address cholestatic and uremic pruritus has been hampered by the lack of basic biological understanding of the relevant mechanisms.

Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector

Retrieved on: 
Tuesday, June 15, 2021
Steroids, Drugs, Adrenal gland disorders, Organ systems, Glucocorticoids, Antipruritics, Hydrocortisone, Ketones, Mineralocorticoids, Autoinjector, Adrenal insufficiency

The ZENEO autoinjector is a revolutionary delivery system, and this product is a terrific strategic fit with our current adrenal insufficiency business.

Key Points: 
  • The ZENEO autoinjector is a revolutionary delivery system, and this product is a terrific strategic fit with our current adrenal insufficiency business.
  • ETON has successfully established strong relations with the patient communities and medical specialists that are its core focus.
  • ZENEO hydrocortisone is expected to be the first and only hydrocortisone autoinjector available for patients that require a rescue dose of hydrocortisone.
  • Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

Mineral Ice® Expands its Portfolio with Maximum Strength Quick Dry Pain-Relieving Foam

Retrieved on: 
Wednesday, June 2, 2021
Physical sciences, Analgesics, Earth sciences, Antipruritics, Cyclohexanols, Menthol, Monoterpenes, Materials, Ice, Pain management

Mineral Ice's 10% Menthol formulation delivers maximum strength pain relief in a new, easy to apply, quick-dry foam.

Key Points: 
  • Mineral Ice's 10% Menthol formulation delivers maximum strength pain relief in a new, easy to apply, quick-dry foam.
  • Acquired by Crown three years ago, the Mineral Ice brand has a rich heritage and continues to be a trusted name in pain relief.
  • By leveraging the benefits of the maximum allowable strength of 10% Menthol, our new Mineral Ice Quick Dry Foam provides even more of the cooling and deep soothing relief for minor muscle aches and joint pain that consumers have depended upon for years.
  • Mineral Ice Quick Dry Foam is now available on Amazon.

Cara Therapeutics to Present at the Jefferies Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021
Drugs, Amines, Antipruritics, Difelikefalin, Piperidines, Chemistry, Investigational New Drug, Functional groups

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com .

Key Points: 
  • A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com .
  • An archived webcast recording will be available on the Cara website for approximately 30 days.
  • Cara Therapeuticsis a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Lazarus Naturals Introduces CBD Muscle Gel to Bring Pain Relief to Aching Muscles

Retrieved on: 
Wednesday, May 19, 2021
Alternative medicine, Health, Retail, Tobacco, Specialty, Analgesics, Antipruritics, Cyclohexanols, Menthol, Monoterpenes, Capsaicin, Drugs, Chemistry, Health care

b'Lazarus Naturals , a leader in the CBD category, announces its newest product, CBD Muscle Gel, offering the cooling properties of menthol along with high-potency, full-spectrum CBD.

Key Points: 
  • b'Lazarus Naturals , a leader in the CBD category, announces its newest product, CBD Muscle Gel, offering the cooling properties of menthol along with high-potency, full-spectrum CBD.
  • View the full release here: https://www.businesswire.com/news/home/20210519005330/en/\nNew CBD Muscle Gel is naturally scented with lemon, orange, sweet basil and eucalyptus, along with functional ingredients like menthol and capsaicin.
  • \xe2\x80\x9cOur Muscle Gel uses cooling agents like menthol for immediate pain relief and then the power of CBD kicks in for anti-inflammatory control.
  • The product is available to purchase at www.lazarusnaturals.com or at select retailers.\nJust like every product from Lazarus Naturals, the CBD Muscle Gel is third-party tested for potency, pesticides and heavy metals.

Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

Retrieved on: 
Thursday, May 6, 2021
Drugs, Opioid receptors, Branches of biology, Opioid peptides, Antipruritics, Amines, Difelikefalin, Chemistry, κ-opioid receptor, Opioid, Prescription Drug User Fee Act

An archived webcast recording will be available on the Cara website for approximately 30 days.\nCara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.

Key Points: 
  • An archived webcast recording will be available on the Cara website for approximately 30 days.\nCara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
  • Cara is developing a novel and proprietary class of product candidates, led by KORSUVA\xe2\x84\xa2 (CR845/difelikefalin), a first-in-class KOR agonist that targets the body\xe2\x80\x99s peripheral nervous system, as well as certain immune cells.
  • The PDUFA target action date for KORSUVA is August 23, 2021.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.\n'

Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

Retrieved on: 
Monday, May 3, 2021
Drugs, Opioid peptides, Antipruritics, Amines, Difelikefalin, Piperidines, Chemistry, Prescription Drug User Fee Act, Functional groups

ET to report first quarter 2021 financial results and provide a corporate update.\nTo participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 5789617.

Key Points: 
  • ET to report first quarter 2021 financial results and provide a corporate update.\nTo participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 5789617.
  • Cara is developing a novel and proprietary class of product candidates, led by KORSUVA\xe2\x84\xa2 (CR845/difelikefalin), a first-in-class KOR agonist that targets the body\xe2\x80\x99s peripheral nervous system, as well as certain immune cells.
  • The PDUFA target action date for KORSUVA is August 23, 2021.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.\n'

Sarna® Launches First-of-Its-Kind Whipped Foam Eczema Relief Therapy

Retrieved on: 
Thursday, April 22, 2021
Organ systems, Steroids, Drugs, Antipruritics, Dermatitis, Skin care, Emollients and protectives, Hydrocortisone, Moisturizer

b'JOHNSON CITY, Tenn., April 22, 2021 /PRNewswire/ -- Crown Therapeutics, a division of Crown Laboratories, is proud to announce the launch of Sarna Eczema Relief Whipped Foam (Hydrocortisone 1%) the first to market over-the-counter whipped foam eczema therapy product.

Key Points: 
  • b'JOHNSON CITY, Tenn., April 22, 2021 /PRNewswire/ -- Crown Therapeutics, a division of Crown Laboratories, is proud to announce the launch of Sarna Eczema Relief Whipped Foam (Hydrocortisone 1%) the first to market over-the-counter whipped foam eczema therapy product.
  • Known for its unique foam delivery system, the moisturizing, light and airy technology delivers fast-acting and quick absorbing relief to itchy, eczema-prone skin.
  • It also uses 1% hydrocortisone, making it a safe and effective therapy for adults, children and those with sensitive skin without needing a prescription.\nThe Sarna Eczema Relief Whipped Foam helps heal eczema flare-ups and provides fast, soothing relief.
  • Sarna products provide powerful itch relief and are safe for everyday use, containing no parabens, dyes or added fragrance.

Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Opioid receptors, Drugs, Branches of biology, Opioid peptides, Antipruritics, Amines, Difelikefalin, Chemistry, κ-opioid receptor, Opioid

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com .

Key Points: 
  • A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com .
  • An archived webcast recording will be available on the Cara website for approximately 30 days.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
  • Difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.